This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
During December 2015-January 2016, the CLL Society conducted a poll among readers of the second issue of The CLL Tribune. The survey included questions assessing participation and/or interest in clinical trials, types of treatment, if any, participation and/or interest in face-to-face support groups, as well as demographic information. 164 complete responses were received:
- Average age – 66 (range 47-89)
- 20% Male, 80% Female
- 95% were patients; 5% were caregivers
- 99% of respondents expressed interested in participating in a face-to-face support group if one was available in their area
Twenty-seven percent of respondents are currently participating or have participated in one or more clinical trials in the past. Almost half would consider participating in a clinical trial in the future. Twenty percent have not yet received any treatment. [Figure 1]
Figure 1. Treatment Status
Thirty-four percent reported that they have been treated with chemotherapy or with chemo-immunotherapy, such as FCR, BR, FR, PCR; chlorambucil with or without R or others or; any of these using the antibodies, obinutuzumab or ofatumumab instead of rituximab. Forty-one percent have not received any treatment yet. [Figure 2] One-quarter of respondents report being treated outside of a clinical trial with a novel agent, such as ibrutinib (Imbruvica) or idelalisib (Zydelig).
Figure 2. Treatment with Chemotherapeutic Agents
Originally published in The CLL Tribune Q1 2016.